ROCKVILLE, Md.--(BUSINESS WIRE)--May. 21, 2012--
Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of
Directors has authorized the repurchase of up to $35 million of the
company’s common stock from time to time on the open market or in
privately negotiated transactions.
“This 35 million stock repurchase program reflects our view that our
shares, at current prices, are substantially undervalued," said Daniel
J. Abdun-Nabi, president and chief executive officer of Emergent
BioSolutions. "This presents an opportunity for creating positive
shareholder returns and long-term shareholder value while maint...